307 related articles for article (PubMed ID: 27433078)
1. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.
Agrawal B; Kumar R
World J Gastroenterol; 2016 Jul; 22(25):5623-6. PubMed ID: 27433078
[TBL] [Abstract][Full Text] [Related]
2. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
3. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
[TBL] [Abstract][Full Text] [Related]
4. Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome.
Delaney WE
Antiviral Res; 2013 Jul; 99(1):34-48. PubMed ID: 23602852
[TBL] [Abstract][Full Text] [Related]
5. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
6. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
Chen G; Wang C; Chen J; Ji D; Wang Y; Wu V; Karlberg J; Lau G
Hepatology; 2017 Jul; 66(1):13-26. PubMed ID: 28195337
[TBL] [Abstract][Full Text] [Related]
8. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents.
Juan J; Feld JJ
Curr Opin Rheumatol; 2014 Jul; 26(4):395-403. PubMed ID: 24841230
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis B and C in children.
El-Shabrawi M; Hassanin F
Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.
Holmes JA; Yu ML; Chung RT
Expert Opin Drug Saf; 2017 Jun; 16(6):651-672. PubMed ID: 28471314
[TBL] [Abstract][Full Text] [Related]
12. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
13. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
16. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
17. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
Degasperi E; Viganò M; Aghemo A; Lampertico P; Colombo M
Expert Rev Anti Infect Ther; 2013 May; 11(5):459-74. PubMed ID: 23627852
[TBL] [Abstract][Full Text] [Related]
18. HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.
Calle Serrano B; Manns MP
Antivir Ther; 2012; 17(6 Pt B):1133-46. PubMed ID: 23188760
[TBL] [Abstract][Full Text] [Related]
19. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
Hofmann WP; Soriano V; Zeuzem S
Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
Soriano V; Barreiro P; Martín-Carbonero L; Castellares C; Ruiz-Sancho A; Labarga P; Ramos B; Gonzalez-Lahoz J
J Infect Dis; 2007 Apr; 195(8):1181-3. PubMed ID: 17357055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
